# Novo Nordisk to acquire Emisphere Technologies for $1.8 billion

Novo Nordisk agreed to acquire Emisphere Technologies for $1.35 billion in cash plus $450 million for related royalty obligations, totaling $1.8 billion. The deal gives Novo Nordisk full ownership of the Eligen drug delivery platform.

- Type: Acquisition
- Announced: 2020-11-06
- Where: Roseland, New Jersey, United States
- Value: $1.80B
- Status: announced
- Products: Eligen drug delivery technology
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novo Nordisk](https://endata.com/companies/17868.md) (acquirer)
- [Emisphere Technologies](https://endata.com/companies/51051.md) (target)

## Sources

- [roi-nj.com](https://www.roi-nj.com/2020/11/06/healthcare/novo-nordisk-buying-roselands-emisphere-and-its-eligen-drug-delivery-platform-in-1-8b-deal/), 2020-11-06: "The acquisition of Emisphere provides Novo Nordisk full ownership of the Eligen SNAC technology, which has been successfully used under a license agreement to develop the first oral biologic, Rybelsus."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.